Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Chemotherapy for prostate carcinoma.

M A Eisenberger1

  • 1Department of Medicine, University of Maryland Cancer Center, Baltimore 21201.

NCI Monographs : a Publication of the National Cancer Institute
|January 1, 1988
PubMed
Summary
This summary is machine-generated.

Chemotherapy offers minimal benefits for advanced prostate cancer (PC) and is not recommended for localized PC. Further research into nonhormonal treatments is necessary due to endocrine-resistant cell clones.

Related Experiment Videos

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Ten-year survival rates by PSA nadir in patients with metastatic hormone-sensitive prostate cancer: long-term survival analysis from the ECOG-ACRIN 3805 (CHAARTED) trial.

Annals of oncology : official journal of the European Society for Medical Oncology·2025
Same author

Muscadine Grape Skin Extract in Biochemically Recurrent Prostate Cancer: A Randomized, Placebo-Controlled, Biomarker-Enriched Trial in Patients With the SOD2 Ala/Ala Variant.

The Prostate·2025
Same author

Clinical outcomes in men of diverse ethnic backgrounds with metastatic castration-resistant prostate cancer.

Annals of oncology : official journal of the European Society for Medical Oncology·2020
Same author

Serial blood-based analysis of AR-V7 in men with advanced prostate cancer.

Annals of oncology : official journal of the European Society for Medical Oncology·2015
Same author

Neutrophil-to-lymphocyte ratio as a prognostic biomarker for men with metastatic castration-resistant prostate cancer receiving first-line chemotherapy: data from two randomized phase III trials.

Annals of oncology : official journal of the European Society for Medical Oncology·2014
Same author

The effect of the frequency and duration of PSA measurement on PSA doubling time calculations in men with biochemically recurrent prostate cancer.

Prostate cancer and prostatic diseases·2013
Same journal

Oral complications following neoadjuvant chemotherapy in patients with head and neck cancer.

NCI monographs : a publication of the National Cancer Institute·1990
Same journal

Studies on the prevention of 5-fluorouracil-induced oral mucositis.

NCI monographs : a publication of the National Cancer Institute·1990
Same journal

Pretreatment oral health care interventions for radiation patients.

NCI monographs : a publication of the National Cancer Institute·1990
Same journal

Prechemotherapy dental treatment to prevent bacteremia.

NCI monographs : a publication of the National Cancer Institute·1990
Same journal

Role of surveillance cultures in prevention and treatment of fungal infections.

NCI monographs : a publication of the National Cancer Institute·1990
Same journal

Oral complications of cancer therapies. Essential aspects of a pretreatment oral examination.

NCI monographs : a publication of the National Cancer Institute·1990
See all related articles

Area of Science:

  • Oncology
  • Urology
  • Medical Research

Background:

  • Prostate carcinoma is a significant health concern.
  • Endocrine resistance is a challenge in advanced prostate cancer treatment.
  • Current treatment strategies for advanced prostate cancer require evaluation.

Purpose of the Study:

  • To evaluate the efficacy of chemotherapy in treating prostate carcinoma.
  • To assess the clinical benefits of chemotherapy in endocrine-resistant stage D2 prostate cancer.
  • To determine the role of chemotherapy as an adjuvant treatment for localized prostate cancer.

Main Methods:

  • Review of data from over 3,000 patients with prostate carcinoma.
  • Analysis of clinical benefits and response rates to various chemotherapy regimens.
  • Evaluation of survival data from prospective randomized clinical trials.

Main Results:

  • Clinical benefits of chemotherapy in endocrine-resistant stage D2 prostate cancer were marginal.
  • Less than 10% of patients showed complete or partial responses to chemotherapy.
  • No survival advantage was observed with chemotherapy compared to control arms in clinical trials.

Conclusions:

  • Chemotherapy is not indicated as an adjuvant treatment for localized prostate cancer.
  • The existence of endocrine-independent cell clones warrants further investigation into nonhormonal cytotoxic treatments.
  • Multidisciplinary collaboration is crucial for developing effective systemic treatments for prostate cancer.